Credit Suisse Group set a $18.00 price objective on AC Immune SA (NASDAQ:ACIU) in a research note published on Wednesday morning. The firm currently has a buy rating on the stock.
Separately, Zacks Investment Research upgraded shares of AC Immune SA from a sell rating to a buy rating and set a $10.00 target price on the stock in a report on Tuesday, May 16th.
Shares of AC Immune SA (NASDAQ:ACIU) traded up 1.60% during mid-day trading on Wednesday, hitting $8.25. The stock had a trading volume of 27,348 shares. AC Immune SA has a 12-month low of $8.02 and a 12-month high of $19.97. The company’s 50 day moving average price is $8.85 and its 200 day moving average price is $10.56. The stock’s market cap is $469.61 million.
AC Immune SA (NASDAQ:ACIU) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.17). The company had revenue of $1.99 million for the quarter, compared to analysts’ expectations of $3.43 million. Equities research analysts predict that AC Immune SA will post ($0.57) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://stocknewstimes.com/2017/07/20/ac-immune-sa-aciu-given-a-18-00-price-target-by-credit-suisse-group-analysts.html.
Several institutional investors have recently bought and sold shares of the stock. FMR LLC raised its position in AC Immune SA by 13.4% in the fourth quarter. FMR LLC now owns 3,637,402 shares of the company’s stock valued at $46,344,000 after buying an additional 428,815 shares during the last quarter. Monashee Investment Management LLC raised its position in AC Immune SA by 74.7% in the first quarter. Monashee Investment Management LLC now owns 30,000 shares of the company’s stock valued at $311,000 after buying an additional 12,832 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in AC Immune SA by 78.4% in the first quarter. Victory Capital Management Inc. now owns 26,757 shares of the company’s stock valued at $277,000 after buying an additional 11,757 shares during the last quarter. Institutional investors and hedge funds own 18.41% of the company’s stock.
About AC Immune SA
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.
